28172-17-0

Usage

Uses

Used in Pharmaceutical Applications:
Tetrahydrocannabivarin 9 is used as a therapeutic agent for various conditions due to its potential health benefits. It is used for:
Mitigating psychoactive effects: THCV is utilized to reduce anxiety and paranoia associated with THC consumption, providing a more balanced experience for users.
Diabetes management: As an appetite suppressant, THCV may help in managing diabetes by controlling blood sugar levels and reducing the risk of complications.
Obesity treatment: Its appetite-suppressing quality makes THCV a potential aid in weight management and obesity treatment, supporting healthier eating habits and weight loss.
Neuroprotection: THCV exhibits neuroprotective properties, suggesting its use in the treatment and management of neurodegenerative diseases such as Alzheimer's and Parkinson's.
Used in Nutraceutical Applications:
In the nutraceutical industry, tetrahydrocannabivarin 9 is used as a dietary supplement for:
Enhancing weight loss programs: Due to its appetite-suppressing effects, THCV can be incorporated into weight loss supplements to support healthier eating patterns and promote weight reduction.
Supporting cognitive health: As a neuroprotective agent, THCV may be used in cognitive health supplements to protect against neurodegenerative diseases and support brain function.
Used in Cosmetic Applications:
In the cosmetic industry, tetrahydrocannabivarin 9 is used as an ingredient in skincare products for:
Anti-aging benefits: The neuroprotective properties of THCV may extend to the skin, potentially offering anti-aging effects by protecting skin cells from oxidative stress and promoting collagen production.
Further research is essential to fully understand the therapeutic potential of tetrahydrocannabivarin 9 and to develop effective formulations and delivery systems for its various applications across different industries.

InChI:InChI=1/C19H26O2/c1-5-6-13-10-16(20)18-14-9-12(2)7-8-15(14)19(3,4)21-17(18)11-13/h9-11,14-15,20H,5-8H2,1-4H3

Upstream product

• 500-49-2 5-propyl-1,3-benzenediol 
• 20053-40-1 cis-Δ²-p-menthene-1,8-diol 
• 1179328-06-3 Δ9-tetrahydrocannabivarin tosylate 
• 55382-52-0 2,4-dihydroxy-6-n-propylbenzoic acid, methyl ester 
• 24274-48-4 cannabidivarin 
• 861892-40-2 (4R)-1-methyl-4-(2-(1-propylene))-2-cyclohexene-2-ol 
• 64898-06-2 (6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene-2-carboxylic acid methyl ester 
• 41395-10-2 1,3-dimethoxy-5-propylbenzene 
• 41497-31-8 3,5-dimethoxyphenyl ethyl ketone 
• 155586-39-3 (3,5-dimethoxyphenyl)-N-methoxy-N-methylcarboxamide 
• 1132-21-4 3,5-dimethoxybenzoic acid 
• 17213-57-9 3,5-dimethoxybenzoyl chloride 
• 1354050-38-6 4-bromo-2,6-dimethoxy-benzaldehyde 

Downstream Products

• 33745-21-0 cannabivarin 
• 96912-65-1 Δ⁹-tetrahydrocannabivarin-11-oic acid 

Relevant academic research and scientific papers

CANNABINOID DERIVATIVES AND PRECURSORS, AND ASYMMETRIC SYNTHESIS FOR SAME

The present disclosure relates to new cannabinoid derivatives and precursors and catalytic asymmetric processes for their preparation. The disclosure also relates to pharmaceutical compositions and pharmaceutical and analytical uses of the new cannabinoid derivatives. For instance, the disclosure relates to the preparation of new precursors, and the use of such precursor compounds for the preparation of isotope labelled cannabinoid products using chiral and achiral catalysts and catalytic processes. The deuterium, carbon-13 and carbon-14 containing compounds can be prepared and purified prior to transformation to the desired individual deuterated cannabinoid products.

CATALYTIC CANNABINOID PROCESSES AND PRECURSORS

The present disclosure relates to new cannabinoid sulfonate esters and processes for their use to prepare cannabinoids. The disclosure also relates to the use of catalysts and catalytic processes for the preparation of cannabinoids from the cannabinoid sulfonate esters.

SYNTHESIS OF PHYTOCANNABINOIDS INCLUDING A DECARBOXYLATION STEP

method for decarboxylating a carboxylated phytocannabinoid compound of Formula I to form a phytocannabinoid compound of Formula II: Formula I Formula II wherein: R1 is selected from the group consisting of: substituted or unsubstituted C1-C5 alkyl; R2 is selected from the group consisting of: OH or O, and R3 is selected from the group consisting of: a substituted or unsubstituted cyclohexene, a substituted or unsubstituted C2-C8 alkene, or a substituted or unsubstituted C2-C8 dialkene; or R2 is O, and R2 and R3 together form a ring structure in which R2 is an internal ring atom; wherein the method includes heating a reaction mixture comprising the carboxylated phytocannabinoid compound and a polar aprotic solvent in the presence of a LiCl for a time sufficient to decarboxylate at least a portion of the carboxylated phytocannabinoid compounds and form the phytocannabinoid compound.

PROCESS FOR THE PRODUCTION OF CANNABIDIOL AND DELTA-9-TETRAHYDROCANNABINOL

The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.

METHOD FOR PURIFYING CANNABINOID COMPOUNDS

The present invention relates to methods for purifying one or two cannabinoid compounds using simulated moving bed chromatography, wherein the cannabinoid compound(s) is/are obtained in the extract and/or the raffinate with the total amount of isomeric impurities being below detection level. In particular, the present invention relates to methods for the purification of cannabidiol, trans-(-)-delta-9-tetrahydrocannabinol, cannabidivarin, trans-(-)-delta-9-tetrahydrocannabivarin and cannabigerol which have been obtained by enantiopure synthesis.

PROCESS FOR THE PREPARATION OF (-) -DELTA 9-TETRAHYDROCANNABINOL

The present disclosure is directed to a process for the chemical synthesis of (-)-Δ9- ^tetrahydrocannabinol (Δ9-THC) and related compounds of formula (I). In particular, the process comprises a one-pot condensation and sulfonylatton

Cannabis. X. The isolation and structures of four new propyl cannabinoid acids, tetrahydrocannabivarinic acid, cannabidivarinic acid, cannabichromevarinic acid and cannabigerovarinic acid, from Thai cannabis, Meao Variant

Four new cannabinoids acids, tetrahydrocannabivarinic acid, cannabidivarinic acid, cannabichromevarinic acid and cannabigerovarinic acid were isolated from Thai Cannabis 'Meao variant' and these structures were elucidated on the basis of chemical and spectral data. This is the first example of the isolation of propyl cannabinoid acid from Cannabis.